NIH Plans to Disband RAC

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 7
Volume 5
Issue 7

Bethesda , Md--NIH director Harold Varmus has announced plants to disband the Recombinant DNA Advisory Committee (RAC). The committee was formed in 1975 as a panel of 24 scientists, ethicists, and others at NIH dedicated to holding those in the field of biogenetics accountable to the public.

Bethesda , Md--NIH director Harold Varmus has announced plantsto disband the Recombinant DNA Advisory Committee (RAC). The committeewas formed in 1975 as a panel of 24 scientists, ethicists, andothers at NIH dedicated to holding those in the field of biogeneticsaccountable to the public.

The RAC created the first safety guidelines for genetically engineeringmicrobes, instituted a formal review system for studies involvinginsertion of new genes into humans, and, in 1990, gave the firstapproval of a human gene therapy experiment. RAC approval wasrequired before the FDA would consider any gene therapy proposal.

Now, Dr. Varmus believes the RAC is no longer necessary, as theFDA can handle all new proposals with the help of ad hoc committeesconvened as needed.

Recent Videos
2 experts are featured in this series.
With many treatments emerging in the EGFR-mutated lung cancer landscape, sequencing therapy has emerged as a key consideration for these patients.
Although a greater risk of CNS relapse may emerge with immunotherapy-based backbones, toxicities associated with chemotherapy are avoided.
Current FDA expectations may allow patients to return to their community physicians at 2 weeks after administration of anitocabtagene autoleucel.
Based on its mechanism of action, anito-cel may cause fewer instances of cytokine release syndrome and delayed toxicities vs other therapies.
2 experts are featured in this series.
Related Content